Founded in 2021, Cellia Science aims to revolutionize hematology by providing rapid and accurate blood cell assays directly at the point of care. The company's core mission is to bring lab-quality blood testing to clinical settings, enabling high-quality visualization and precise quantitative measurement of all blood cell types within minutes. Utilizing a label-free technology, Cellia Science focuses on enhancing patient care by delivering immediate results, thereby improving diagnostic efficiency and treatment outcomes.
Cellia Science has garnered attention from notable figures in the medical and tech industries, although specific names and investors are not publicly disclosed. The startup's key achievement lies in the development of its first device, which promises to transform point-of-care diagnostics. By significantly reducing the time required for blood cell analysis, Cellia Science is poised to make a substantial impact on healthcare delivery, particularly in urgent and remote settings.
